Bristol-Myers receives FDA approval for Erbitux use in KRAS wild-type cancer
KRAS mutation-negative colorectal cancer is also commonly known as KRAS wild-type. Concurrently, the FDA has also approved the first KRAS companion diagnostic test, the therascreen KRAS diagnostic kit